Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5877876 | The Journal of Pain | 2013 | 13 Pages |
Abstract
The analgesia obtained from a low dose of delta-9-tetrahydrocannabinol (1.29%) in patients, most of whom were experiencing neuropathic pain despite conventional treatments, is a clinically significant outcome. In general, the effect sizes on cognitive testing were consistent with this minimal dose. As a result, one might not anticipate a significant impact on daily functioning.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Barth Wilsey, Thomas Marcotte, Reena Deutsch, Ben Gouaux, Staci Sakai, Haylee Donaghe,